Table 2. Study design and primary endpoints of clinical trials involving gastrectomy for GC as found on ClinicalTrials.gov as of 1 May 2020.

	NA	Phase I	Phase I/II	Phase II	Phase II/III	Phase III	Phase IV	Total (%)
Interventional mode
Single group assignment	10	-	2	12	-	1	-	25 (18%)
Parallel assignment	52	2	1	14	3	40	1	113 (82%)
Treatment allocation
Nonrandomised	6	-	-	-	1	1	-	8 (6%)
Randomised	49	2	1	14	2	39	1	108 (78%)
Not specified	7	-	2	12	-	1	-	22 (16%)
Masking
Open label (none)	42	-	2	24	3	36	-	107 (78%)
Masked	20	2	-	2	-	5	1	30 (22%)
Not specified	-	-	1	-	-	-	-	1 (1%)
Main primary endpoint
30-day reoperation	1	-	-	-	-	-	-	1 (1%)
Number of harvested lymph nodes	5	-	1	5	-	3	-	14 (10%)
Operation time	4	-	-	1	-	1	-	6 (4%)
Overall survival	4	-	-	4	2	15	-	25 (18%)
Percentage body weight ratio	-	-	-	-	-	1	-	1 (1%)
Postoperative length of stay	3	-	-	1	-	1	-	5 (4%)
Postoperative morbidity	6	-	1	2	-	2	-	11 (8%)
Postoperative outcomes	16	-	-	5	-	3	1	25 (18%)
Progression-free survival	17	1	-	7	1	12	-	38 (28%)
Quality of life	3	1	-	1	-	3	-	8 (6%)
Rate of conversion	-	-	1	-	-	-	-	1 (1%)
Time to drain removal	1	-	-	-	-	-	-	1 (1%)
Tumour recurrence rate	2	-	-	-	-	-	-	2 (1%)